Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / EFNA5

EFNA5

Basics

Aliases:
This biomarker is also known as:
  • EPH-related receptor tyrosine kinase ligand 7,
  • RAGS,
  • AF1,
  • EFL5,
  • AL-1,
  • LERK7,
  • GLC1M,
  • eph-related receptor tyrosine kinase ligand 7,
  • LERK-7,
  • EPLG7,
  • ephrin-A5,

View in BioMuta

Description…

EFNA5 is a cell surface-bound member of the ephrin gene family. Ephrins are proteins that function as ligands for the ephrin receptors (Eph receptors). Eph receptors are a family of receptor tyrosine kinases which are crucial for migration, repulsion and adhesion during neuronal, vascular and epithelial development. Based on their structures and sequence relationships, ephrins are divided into the ephrin-A (EFNA) class, which are anchored to the membrane by a glycosylphosphatidylinositol linkage, and the ephrin-B (EFNB) class, which are transmembrane proteins.

Attributes

QA State: Curated
Type: Protein
Short Name:

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Breast

Attributes

Phase: Two
QA State: Under Review

Overview

No additional breast data available.

Performance Comment

EFNA5 was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

News

The final report of the 2013 Cancer Biomarkers Bioinformatics Workshop is now available.

Announcement 03/06/2014

Thank you to everyone who helped make the 27th EDRN Steering Committee Meeting a success. We look forward to seeing everyone at the 9th EDRN Scientific Workshop from September 8-11, 2014 in Washington D.C.

Announcement